Knowledge and use of hormone replacement therapy among Polish women: Estimates from a nationally representative study - HORTPOL 2002

Maturitas

Volumn 47, Issue 1, 2004, Pages 31-37

  Rachoń, Dominik ^a   Zdrojewski, Tomasz ^a   Suchecka Rachoń, Krystyna ^a   Szpakowski, Pawe ^a   Bandosz, Piotr ^a   Manikowski, Adam ^b   Wyrzykowski, Bogdan ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Center for Social Research in Sopot   (Poland)

Author keywords

Hormone replacement therapy; Menopause; Poland; Postmenopausal women

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; LEVONORGESTREL; SEX HORMONE;

ACADEMIC ACHIEVEMENT; ADULT; AGED; BREAST CANCER; CANCER RISK; DRUG USE; FEMALE; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HORMONE SUBSTITUTION; HUMAN; INVOLUTIONAL DEPRESSION; MENOPAUSAL SYNDROME; POLAND; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; UTERUS CANCER;

EID: 0346998040     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00222-6     Document Type: Article

References (37)

1. Ettinger B., Friedman G.D., Bush T., Quesenberry C.P. Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet. Gynecol. 87:1996;6-12.
2. Brinton L.A., Schairer C. Postmenopausal hormone-replacement therapy - time for a reappraisal. New Engl. J. Med. 336:1997;1821-1822.
3. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., Allan J.D. Postmenopausal hormone replacement therapy: scientific review. J. Am. Med. Assoc. 288:2002;872-881.
4. Voelker R. Questions about hormone therapy remain puzzling. J. Am. Med. Assoc. 288:2002;2395-2396.
5. Risks and benefits of estrogen plus progestins in healthy postmenopausal women. J. Am. Med. Assoc. 288:2002;321-333.
6. Brett K.M., Madans J.H. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am. J. Epidemiol. 145:1997;536-545.
7. Csizmandi I., Benedetti A., Boivin J.F., Hanley J.A., Collet J.P. Use of postmenopausal estrogen replacement therapy from 1981 to 1997. Can. Med. Assoc. J. 166:2002;187-188.
8. Hartley H.O., Rao J.N. Sampling with unequal probabilities. Ann. Mathemat. Stat. 33:1962;350-374.
9. Cauley J.A., Cummings S.F., Black D.M., Mascioli S.R., Seeley D.G. Prevalence and determinants of estrogen replacement therapy in elderly women. Am. J. Obstet. Gynecol. 163:1990;1438-1444.
10. Scalley E.K., Henrich J.B. An overview of estrogen replacement therapy in postmenopausal women. J. Womens Health. 2:1993;289-294.
11. Matthews K.A., Kuller L.H., Wing R.R., Meilahn E.N., Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers. Am. J. Epidemiol. 143:1996;971-978.
12. Keating N.L., Cleary P.D., Rossi A.S., Zaslavsky A.M., Ayanian J.Z. Use of hormone replacement therapy by postmenopausal women in the United States. Ann. Intern. Med. 130:1999;545-553.
13. Mueller J.E., Doring A., Heier M., Lowel H. Prevalence and determinants of hormone replacement therapy in German women 1984-1995. Maturitas. 43:2002;95.
14. Oddens B.J., Boulet M.J. Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants, and compliance. Obstet. Gynecol. 90:1997;269-277.
15. Bakken K., Eggen A.E., Lund E. Hormone replacement therapy in Norwegian women 1996-1997. Maturitas. 40:2001;131-141.
16. Li C., Samsioe G., Lidfelt J., Nerbrand C., Agardh C.D. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women's Health in Lund Area (WHILA) Study. Menopause. 7:2000;273-281.
17. Chiaffarino F., Parazzini F., La Vecchia C., et al. Correlates of hormone replacement therapy use in Italian women 1992-1996. Maturitas. 33:1999;107-115.
18. Benet Rodriguez M., Carvajal Garcia-Pando A., Garcia Del Pozo J., Alvarez Requejo A., Vega Alonso T. Hormonal replacement therapy in Spain. Med. Clin. (Barcelona). 119:2002;4-8.
19. Groeneveld F.P., Bareman F.P., Barentsen R., Dokter H.J., Drogendijk A.C., Hoes A.W. Duration of hormonal replacement therapy in general practice: a follow-up study. Maturitas. 29:1998;125-131.
20. Wardell D.W., Engebretsson J.C. Women's anticipations of hormonal replacement therapy. Maturitas. 22:1995;177-183.
21. Crosignani P.G. Management of hormone replacement therapy: the Italian experience. Eur. J. Obstet. Gynecol. Reprod. Biol. 64:(Suppl):1996;13-15.
22. Oddens B.J., Boulet M.J., Lehert P., Visser A.P. Has the climacteric been medicalized? A study on the use of medication for climacteric complaints in four countries. Maturitas. 15:1992;171-181.
23. Oddens B.J., Boulet M.J., Lehert P., Visser A.P. A study on the use of medication for climacteric complaints in western Europe-II. Maturitas. 19:1994;1-12.
24. Suarez-Almazor M., Homik J.E., Messina D., Davis P. Attitudes and beliefs of family physicians and gynecologists in relation to the prevention and treatment of osteoporosis. J. Bone Miner. Res. 12:1997;1100-1107.
25. Andersson K., Pedersen A.T., Mattsson L.A., Milsom I. Swedish gynecologists' and general practitioners' views on the climacteric period: knowledge, attitudes and management strategies. Acta Obstet. Gynecol. Scand. 77:1998;909-916.
26. Mattsson L.A., Stadberg E., Milsom I. Management of hormone replacement therapy: the Swedish experience. Eur. J. Obstet. Gynecol. Reprod. Biol. 64:(Suppl):1996;S3-S5.
27. Barentsen R. The climacteric in The Netherlands: a review of Dutch studies on epidemiology, attitudes and use of hormone replacement therapy. Eur. J. Obstet. Gynecol. Reprod. Biol. 64:(Suppl.):1996;7-11.
28. Topo P., Hemminki E., Uutela A. Women's choice and physicians' advice on use of menopausal and postmenopausal hormone therapy. Int. J. Health Sci. 4:1993;101-109.
29. Exline J.L., Siegler I.C., Bastian L.A. Differences in providers' beliefs about benefits and risks of hormone replacement therapy in managed care. J. Womens Health. 7:1998;879-884.
30. Sogaard A.J., Tollan A., Berntsen G.K.R., Fonnebo V., Magnus J.H. Hormone replacement therapy: knowledge, attitudes, self-reported use - and sales figures in Nordic women. Maturitas. 35:2000;201-214.
31. Hunskaar S., Backe B. Attitudes towards and level of information on perimenopausal and postmenopausal hormone replacement therapy among Norwegian women. Maturitas. 15:1992;183-194.
32. Schneider H.P. Cross-national study of women's use of hormone replacement therapy (HRT) in Europe. Int. J. Fertil. Womens Med. 42:(Suppl 2):1997;365-375.
33. Ringa V., Ledesert B., Gueguen R., Schiele F., Breart G. Determinants of hormonal replacement therapy in recently postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol. 45:(3):1992;193-200.
34. Kreling D., Mott D., Wiederholt J., Lundy J., Levitt L. Prescription drug trends a chartbook update. 2001;Kaiser Family Foundation, Menl Park, CA.
35. Schwartz M., Anwah I., Levy R.N. Variations in treatment of postmenopausal osteoporosis. Clin. Orthop. 192:1985;180-184.
36. Greendale G.A., Carlson K.J., Schiff I. Estrogen and progestin therapy to prevent osteoporosis: attitudes and practices of general internists and gynecologists. J. Gen. Intern. Med. 5:1990;464-469.
37. Stafford R.S., Saglam D., Causino N., Blumenthal D. Low rates of hormone replacement in visits to United States primary care physicians. Am. J. Obstet. Gynecol. 177:1997;381-387.